Refine
Has Fulltext
- yes (8)
Is part of the Bibliography
- yes (8)
Document Type
- Journal article (8)
Language
- English (8)
Keywords
- heart failure (3)
- acute heart failure (2)
- left ventricular ejection fraction (2)
- morbidity (2)
- mortality (2)
- ACC/AHA classification (1)
- COPD diagnosis (1)
- CardioMEMS™ HF system (1)
- Comorbidities (1)
- Diastocic Dysfunction (1)
- Eplerenone (1)
- Framingham (1)
- GOLD (1)
- Heart failure with preserved ejection fraction (1)
- Heart failure with reduced ejection fraction (1)
- Hyperkalemia (1)
- Medizin (1)
- Morbidity (1)
- Mortality (1)
- Myocardial-Infarction (1)
- Outcomes (1)
- Physical impairment (1)
- Predictors (1)
- Preserved Ejection Fraction (1)
- adaptive immune response (1)
- anaemia (1)
- anti-myocardial (1)
- autoantibody (1)
- chronic kidney disease (1)
- comorbidity (1)
- depression (1)
- haemodynamic monitoring (1)
- health‐related quality of life (1)
- inflammation (1)
- lower limit of normal (1)
- natriuretic peptide (1)
- recovery (1)
- sex differences (1)
- validation (1)
Background:
To assess heart failure therapies in diabetic patients with preserved as compared to impaired systolic ventricular function.
Methods:
3304 patients with heart failure from 9 different studies were included (mean age 63 +/- 14 years); out of these, 711 subjects had preserved left ventricular ejection fraction (>= 50%) and 994 patients in the whole cohort suffered from diabetes.
Results:
The majority (>90%) of heart failure patients with reduced ejection fraction (SHF) and diabetes were treated with an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) or with beta-blockers. By contrast, patients with diabetes and preserved ejection fraction (HFNEF) were less likely to receive these substance classes (p < 0.001) and had a worse blood pressure control (p < 0.001). In comparison to patients without diabetes, the probability to receive these therapies was increased in diabetic HFNEF patients (p < 0.001), but not in diabetic SHF patients. Aldosterone receptor blockers were given more often to diabetic patients with reduced ejection fraction (p < 0.001), and the presence and severity of diabetes decreased the probability to receive this substance class, irrespective of renal function.
Conclusions:
Diabetic patients with HFNEF received less heart failure medication and showed a poorer control of blood pressure as compared to diabetic patients with SHF. SHF patients with diabetes were less likely to receive aldosterone receptor blocker therapy, irrespective of renal function.